SG11201608371RA - A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline - Google Patents

A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Info

Publication number
SG11201608371RA
SG11201608371RA SG11201608371RA SG11201608371RA SG11201608371RA SG 11201608371R A SG11201608371R A SG 11201608371RA SG 11201608371R A SG11201608371R A SG 11201608371RA SG 11201608371R A SG11201608371R A SG 11201608371RA SG 11201608371R A SG11201608371R A SG 11201608371RA
Authority
SG
Singapore
Prior art keywords
hexanediyl
dioxo
prodrug
proline
bis
Prior art date
Application number
SG11201608371RA
Other languages
English (en)
Inventor
Alexis Denis
Olivier Mirguet
Jérôme Toum
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of SG11201608371RA publication Critical patent/SG11201608371RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201608371RA 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline SG11201608371RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound
PCT/EP2015/058998 WO2015165833A1 (fr) 2014-04-29 2015-04-27 Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Publications (1)

Publication Number Publication Date
SG11201608371RA true SG11201608371RA (en) 2016-11-29

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608371RA SG11201608371RA (en) 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Country Status (26)

Country Link
US (3) US9701668B2 (fr)
EP (1) EP3137457B1 (fr)
JP (1) JP6445046B2 (fr)
KR (1) KR20160145617A (fr)
CN (1) CN106459016B (fr)
AR (1) AR100204A1 (fr)
AU (1) AU2015252184B2 (fr)
BR (1) BR112016025129A2 (fr)
CA (1) CA2947060C (fr)
CL (1) CL2016002721A1 (fr)
CR (1) CR20160508A (fr)
DO (1) DOP2016000292A (fr)
EA (1) EA032129B1 (fr)
ES (1) ES2731253T3 (fr)
GB (1) GB201407506D0 (fr)
IL (2) IL248249A0 (fr)
MA (1) MA39406B1 (fr)
MX (1) MX2016014246A (fr)
MY (1) MY191088A (fr)
PE (1) PE20161558A1 (fr)
PH (1) PH12016502006B1 (fr)
SG (1) SG11201608371RA (fr)
TW (1) TWI676624B (fr)
UA (1) UA119871C2 (fr)
UY (1) UY36098A (fr)
WO (1) WO2015165833A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) * 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0915088T1 (en) 1997-10-31 2002-12-31 F. Hoffmann-La Roche Ag D-proline derivatives
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
EP1636240A1 (fr) 2003-06-05 2006-03-22 Pfizer Products Inc. Promedicament inhibiteur de la beta-lactamase
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
EP1870412A4 (fr) 2005-04-12 2009-12-30 Meiji Seika Kaisha Dérivé de 2-thioéthénylcarbapénème
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Also Published As

Publication number Publication date
KR20160145617A (ko) 2016-12-20
WO2015165833A1 (fr) 2015-11-05
EP3137457B1 (fr) 2019-04-17
JP2017514829A (ja) 2017-06-08
EP3137457A1 (fr) 2017-03-08
US10597385B2 (en) 2020-03-24
MA39406A1 (fr) 2017-07-31
CN106459016A (zh) 2017-02-22
CA2947060A1 (fr) 2015-11-05
BR112016025129A2 (pt) 2017-08-15
MA39406B1 (fr) 2018-04-30
GB201407506D0 (en) 2014-06-11
PH12016502006A1 (en) 2016-12-19
IL248249A0 (en) 2016-11-30
UY36098A (es) 2015-11-30
AU2015252184A1 (en) 2016-10-27
US9701668B2 (en) 2017-07-11
MY191088A (en) 2022-05-30
ES2731253T3 (es) 2019-11-14
PE20161558A1 (es) 2017-01-06
TWI676624B (zh) 2019-11-11
CL2016002721A1 (es) 2017-01-20
EA032129B1 (ru) 2019-04-30
US20160075694A1 (en) 2016-03-17
MX2016014246A (es) 2017-02-06
UA119871C2 (uk) 2019-08-27
US9873686B2 (en) 2018-01-23
CA2947060C (fr) 2023-09-26
AR100204A1 (es) 2016-09-21
PH12016502006B1 (en) 2016-12-19
JP6445046B2 (ja) 2018-12-26
EA201692185A1 (ru) 2017-06-30
TW201625598A (zh) 2016-07-16
DOP2016000292A (es) 2017-11-15
US20180099955A1 (en) 2018-04-12
IL279120A (en) 2021-01-31
CN106459016B (zh) 2019-11-01
US20170267665A1 (en) 2017-09-21
CR20160508A (es) 2017-03-10
AU2015252184B2 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
NO2021035I1 (no) Risdiplam or a pharmaceutically acceptable salt thereof
HRP20181938T1 (hr) Sistem za lateralnu stabilnost
ZA201605622B (en) 1,3-benzodioxole derivative
MA42036A (fr) Analogues nucléosidiques 5'-substitués
GB201620546D0 (en) A distributed ledger
IL251976A0 (en) Phage therapy
IL279120A (en) 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline prodrug
GB201614571D0 (en) Speckle reduction
PT3131910T (pt) Utilização de um composto de fosforamidato de 1,3,5-triazina- 2-ilo na síntese de sofosbuvir
SG11201608986WA (en) A locking gimbal
EP3164136A4 (fr) Composés de promédicaments et leurs utilisations
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
GB201612872D0 (en) Prodrug compounds
IL267264A (en) Auxiliary substances
IL259073A (en) History of abscisic acid - converted at the 3' position
GB201521215D0 (en) Prodrug
SI3155169T1 (sl) CF papir
GB201621375D0 (en) Adjuvants
GB201618479D0 (en) Adjuvants
EP3210974A4 (fr) Promédicament
GB2531817B (en) Accelerometer
GB201608531D0 (en) Cheques
AP2016009534A0 (en) A locking gimbal
GB201517690D0 (en) Tissue Paper
GB201521036D0 (en) Calligrapy Paper